Trial reportJournal of thrombosis and thrombolysis2009
Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients.
Trial report in Journal of thrombosis and thrombolysis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- The effect of acarbose on inflammatory cytokines and adipokines in adults: a systematic review and meta-analysis of randomized clinical trials.Inflammopharmacology · 2024Pooled it
- Extracellular vesicles: mechanisms and prospects in type 2 diabetes and its complications.Frontiers in endocrinology · 2024Review
- Review
- Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease.Frontiers in pharmacology · 2021Review
- Interplay between Endoplasmic Reticulum Stress and Large Extracellular Vesicles (Microparticles) in Endothelial Cell Dysfunction.Biomedicines · 2020Review
- Endoplasmic Reticulum (ER) Stress-Generated Extracellular Vesicles (Microparticles) Self-Perpetuate ER Stress and Mediate Endothelial Cell Dysfunction Independently of Cell Survival.Frontiers in cardiovascular medicine · 2020Article
- Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives.International journal of molecular sciences · 2019Review
- Molecular Mechanisms Underpinning Microparticle-Mediated Cellular Injury in Cardiovascular Complications Associated with Diabetes.Oxidative medicine and cellular longevity · 2019Review
- The Contrasting Role of Extracellular Vesicles in Vascular Inflammation and Tissue Repair.Frontiers in pharmacology · 2019Review
- Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor βJournal of blood medicine · 2019Article
- Pathogenic roles of microvesicles in diabetic retinopathy.Acta pharmacologica Sinica · 2018Review
- The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles.Cardiovascular drugs and therapy · 2017Review
- Hypoglycemic agents and potential anti-inflammatory activity.Journal of inflammation research · 2016Review
- Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2015Article
- Microvesicles and diabetic complications--novel mediators, potential biomarkers and therapeutic targets.Acta pharmacologica Sinica · 2014Review
- α-Glucosidase inhibitors and their use in clinical practice.Archives of medical science : AMS · 2012Article
- Effects of blood pressure and the renin-angiotensin system on platelet activation in type 2 diabetes.Journal of diabetes investigation · 2010Article
- Microparticles and cardiovascular diseases.Annals of medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-derived microparticles (PDMP), selectins, and adiponectin play an important role in the development of atherosclerosis in diabetes. Acarbose has been shown to have a beneficial effect on postprandial hyperglycemia in diabetic patients. However, its influence on PDMP, selectins, and adiponectin in these patients is poorly understood. We investigated the effect of acarbose on circulating levels of PDMP, selectins, and adiponectin in patients with type 2 diabetes. Acarbose (300 mg/day) was administered for 3 months. Levels of PDMP, sP-selectin, sL-selectin, and adiponectin were measured by ELISA at baseline and after 1 and 3 months of treatment. The levels of PDMP, sP-selectin, and sL-selectin were higher in diabetic patients than in hypertensive patients (PDMP; 35.1 +/- 34.2 vs. 53.3 +/- 56.7 U/ml, P < 0.05: sP-selectin; 134 +/- 52 vs. 235 +/- 70 ng/dl, P < 0.01: sL-selectin; 569 +/- 183 vs. 805 +/- 146 ng/ml, P < 0.05), while there were no significant differences between hypertensive and hyperlipidemic patients. Before acarbose treatment, the adiponectin level of diabetic patients was lower than that of hypertensive patients. Acarbose therapy significantly decreased the plasma PDMP level relative to baseline. Acarbose also caused a significant decrease of sP-selectin and sL-selectin. On the other hand, acarbose therapy led to a significant increase of adiponectin after 3 months of administration compared with baseline (adiponectin: diabetes versus hypertension, 3.61 +/- 1.23 vs. 5.87 +/- 1.92 microg/ml, P < 0.05; diabetes versus controls, 2.81 +/- 0.95 vs. 6.13 +/- 1.24 microg/ml, P < 0.01). Twelve of the 30 diabetic patients had a history of thrombotic complications. Furthermore, the reduction of PDMP and selectins during acarbose therapy was significantly greater in the thrombotic group (12 of 30) than in the nonthrombotic group (18 of 30) of diabetic patients. Acarbose may be beneficial for primary prevention of atherothrombosis in patients with type 2 diabetes. However, it requires a large clinical trial to test this hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.